FPMI Stock Overview
FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
FluoroPharma Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0008 |
| 52 Week Low | US$0.0001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 3 Year Change | -97.83% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| FPMI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.0% | 1.2% |
| 1Y | n/a | 0.7% | 24.9% |
Return vs Industry: Insufficient data to determine how FPMI performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how FPMI performed against the US Market.
Price Volatility
| FPMI volatility | |
|---|---|
| FPMI Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FPMI's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine FPMI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Thom Tulip | www.fluoropharma.com |
FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies.
FluoroPharma Medical, Inc. Fundamentals Summary
| FPMI fundamental statistics | |
|---|---|
| Market cap | US$2.76k |
| Earnings (TTM) | -US$2.57m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs FPMI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FPMI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.57m |
| Earnings | -US$2.57m |
Last Reported Earnings
Dec 31, 2016
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did FPMI perform over the long term?
See historical performance and comparison